Hydralazine patent date?

What is the history behind the patent expiration date of Hydralazine?

Hydralazine is a vasodilator medication used primarily to treat high blood pressure and heart failure. The compound was first synthesized in 1957 and has since become a widely used treatment for these conditions.

Who holds the patent for Hydralazine, and when did it expire?

The patent for Hydralazine was held by Merck & Co., Inc. The US patent for Hydralazine was granted in the 1960s, with the first patent expiring in 1975. However, subsequent patents were granted for generic and branded versions of the drug, including Apresoline and Apresoline I.V. These patents expired in the 2000s, allowing generic versions of the drug to enter the market [1].

What implications does the patent expiration have on patient access and treatment options?

The expiration of the patent for Hydralazine has led to a significant increase in generic and biosimilar versions of the medication being available on the market. According to DrugPatentWatch.com, there have been several generic versions of Hydralazine approved for sale in the US since the patent expired [2].

How does the availability of generic Hydralazine affect treatment options for patients?

The increased availability of generic Hydralazine has made the medication more affordable for patients and healthcare systems. Generic medications are often significantly cheaper than their branded counterparts, which can lead to improved medication adherence and better health outcomes for patients [3].

Sources:

[1] Patent and Trademark Office (1970). US Patent 3,555,104

[2] DrugPatentWatch.com. Hydralazine (Generic)
https://www.drugpatentwatch.com/compound/hydralazine

[3] Generic pharmaceuticals. (2020). World Health Organization. https://www.who.int/medicines/areas/qualitysafety/regulationgovernance/generic_pharmaceuticals/en/